JP2004538319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004538319A5 JP2004538319A5 JP2003518438A JP2003518438A JP2004538319A5 JP 2004538319 A5 JP2004538319 A5 JP 2004538319A5 JP 2003518438 A JP2003518438 A JP 2003518438A JP 2003518438 A JP2003518438 A JP 2003518438A JP 2004538319 A5 JP2004538319 A5 JP 2004538319A5
- Authority
- JP
- Japan
- Prior art keywords
- nsaid
- flurbiprofen
- ester
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 17
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 12
- 150000002148 esters Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 239000005022 packaging material Substances 0.000 claims 5
- 230000036436 anti-hiv Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims 4
- -1 lamivulin Chemical compound 0.000 claims 4
- SYTBZMRGLBWNTM-JTQLQIEISA-N (S)-flurbiprofen Chemical compound FC1=CC([C@@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-JTQLQIEISA-N 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- DKYWVDODHFEZIM-LLVKDONJSA-N (2r)-2-(3-benzoylphenyl)propanoic acid Chemical compound OC(=O)[C@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-LLVKDONJSA-N 0.000 claims 2
- NNYBQONXHNTVIJ-QGZVFWFLSA-N (R)-etodolac Chemical compound C1CO[C@](CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-QGZVFWFLSA-N 0.000 claims 2
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 2
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims 2
- 229960004748 abacavir Drugs 0.000 claims 2
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 2
- 229960005430 benoxaprofen Drugs 0.000 claims 2
- 229960003184 carprofen Drugs 0.000 claims 2
- 229960005319 delavirdine Drugs 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 2
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 claims 2
- 229960001936 indinavir Drugs 0.000 claims 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims 2
- 229960004187 indoprofen Drugs 0.000 claims 2
- 229960002009 naproxen Drugs 0.000 claims 2
- 229960000884 nelfinavir Drugs 0.000 claims 2
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical group O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 2
- 229960000311 ritonavir Drugs 0.000 claims 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 2
- 229960001852 saquinavir Drugs 0.000 claims 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims 2
- 229960001203 stavudine Drugs 0.000 claims 2
- 229960004492 suprofen Drugs 0.000 claims 2
- 229960004556 tenofovir Drugs 0.000 claims 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 2
- 229960002555 zidovudine Drugs 0.000 claims 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 2
- 108010002459 HIV Integrase Proteins 0.000 claims 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30253301P | 2001-06-29 | 2001-06-29 | |
| US10/186,371 US20030027867A1 (en) | 2001-06-29 | 2002-06-28 | Use of R-NSAID compounds for anti-HIV treatment |
| PCT/US2002/022289 WO2003013424A2 (en) | 2001-06-29 | 2002-07-01 | Use of r-nsaid compounds for anti-hiv treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004538319A JP2004538319A (ja) | 2004-12-24 |
| JP2004538319A5 true JP2004538319A5 (enExample) | 2006-01-05 |
Family
ID=26882034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003518438A Withdrawn JP2004538319A (ja) | 2001-06-29 | 2002-07-01 | 抗−hiv治療のためのr−nsaid化合物の用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030027867A1 (enExample) |
| EP (1) | EP1420745A2 (enExample) |
| JP (1) | JP2004538319A (enExample) |
| AU (1) | AU2002322481A1 (enExample) |
| CA (1) | CA2451691A1 (enExample) |
| WO (1) | WO2003013424A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060004086A1 (en) * | 2000-04-13 | 2006-01-05 | Mayo Foundation For Medical Education And Research | Method of reducing Abeta42 and treating diseases |
| EP1284729A4 (en) * | 2000-04-13 | 2007-12-19 | Mayo Foundation | A- (BETA) -42 DECREASING MEDICINAL PRODUCTS |
| WO2004032845A2 (en) * | 2002-10-07 | 2004-04-22 | Encore Pharmaceuticals, Inc. | R-nsaid esters and their use |
| WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
| CA2532207A1 (en) * | 2003-07-11 | 2005-07-21 | Myriad Genetics, Inc. | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
| WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
| WO2005108683A1 (en) * | 2004-04-29 | 2005-11-17 | Keystone Retaining Wall Systems, Inc. | Veneers for walls, retaining walls and the like |
| WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| BRPI0514303A (pt) * | 2004-08-11 | 2008-06-10 | Myriad Genetics Inc | composição farmacêutica e método para tratar distúrbios neurodegenerativos |
| CA2615063A1 (en) * | 2005-07-22 | 2007-02-01 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
| US8110681B2 (en) * | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| WO2008006099A2 (en) * | 2006-07-07 | 2008-01-10 | Myriad Genetics, Inc. | Treatment of psychiatric disorders |
| GB2475359A (en) * | 2009-11-11 | 2011-05-18 | Biocopea Ltd | A compound for use in treating a fulminant respiratory disorder |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1091403A (en) * | 1964-01-24 | 1967-11-15 | Boots Pure Drug Co Ltd | Therapeutically active phenylalkane derivatives |
| FR1546478A (fr) * | 1967-01-27 | 1968-11-22 | Rhone Poulenc Sa | Nouveaux dérivés de l'acide benzoyl-3 phénylacétique et leur préparation |
| US4089969A (en) * | 1976-07-14 | 1978-05-16 | Syntex (U.S.A.) Inc. | 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof |
| US4230724A (en) * | 1979-07-16 | 1980-10-28 | Allergan Pharmaceuticals, Inc. | Method of treating vascularization of the eye with Flurbiprofen |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPH0610141B2 (ja) * | 1986-02-14 | 1994-02-09 | 新技術事業団 | エイズウイルス性疾患処置剤 |
| DE3824353A1 (de) * | 1988-07-19 | 1990-01-25 | Paz Arzneimittelentwicklung | Verfahren zur trennung von gemischen enantiomerer arylpropionsaeuren |
| JPH0248526A (ja) * | 1988-08-08 | 1990-02-19 | Sumitomo Pharmaceut Co Ltd | インドメタシン注射剤およびその製造方法 |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| DE4028906A1 (de) * | 1990-09-12 | 1992-03-19 | Paz Arzneimittelentwicklung | Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen |
| DE4140184C2 (de) * | 1991-12-05 | 1995-12-21 | Alfatec Pharma Gmbh | Akutform für ein Flurbiprofen enthaltendes Arzneimittel |
| US5331000A (en) * | 1992-03-09 | 1994-07-19 | Sepracor Inc. | Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen |
| WO1993017680A1 (en) * | 1992-03-13 | 1993-09-16 | Sepracor, Inc. | Antipyretic and analgesic methods and compositions containing optically pure r-etodolac |
| DE4216756C2 (de) * | 1992-05-21 | 1994-08-25 | Pharmatrans Sanaq Ag | 2-Arylpropionsäure-Zubereitungen und Verfahren zu ihrer Herstellung |
| US5382591A (en) * | 1992-12-17 | 1995-01-17 | Sepracor Inc. | Antipyretic and analgesic methods using optically pure R-ketorolac |
| DK169670B1 (da) * | 1992-12-22 | 1995-01-09 | Cheminova Agro As | Fremgangsmåde til fremstilling af 2,3,5,6-tetrachlorpyridin |
| US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| US5981592A (en) * | 1995-03-13 | 1999-11-09 | Loma Linda University Medical Center | Method and composition for treating cystic fibrosis |
| US6160018A (en) * | 1995-03-13 | 2000-12-12 | Loma Linda University Medical Center | Prophylactic composition and method for alzheimer's Disease |
| US5955504A (en) * | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
| US5677469A (en) * | 1995-05-18 | 1997-10-14 | Sepracor, Inc. | Process for resolving chiral acids with 1-aminoindan-2-ols |
| US5858738A (en) * | 1996-11-07 | 1999-01-12 | Merck & Co., Inc. | Ermophilane sesquiterpenoids as HIV intergrase inhibitors |
| US6331610B1 (en) * | 1997-04-25 | 2001-12-18 | Metatron, Inc. | Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin |
| US6140349A (en) * | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| WO2000013684A2 (en) * | 1998-09-03 | 2000-03-16 | Loma Linda University Medical Center | Pharmaceutical composition and method for treatment of inflammation |
| IN189741B (enExample) * | 1998-11-09 | 2003-04-19 | Council Scient Ind Res |
-
2002
- 2002-06-28 US US10/186,371 patent/US20030027867A1/en not_active Abandoned
- 2002-07-01 JP JP2003518438A patent/JP2004538319A/ja not_active Withdrawn
- 2002-07-01 WO PCT/US2002/022289 patent/WO2003013424A2/en not_active Ceased
- 2002-07-01 CA CA002451691A patent/CA2451691A1/en not_active Abandoned
- 2002-07-01 EP EP02756473A patent/EP1420745A2/en not_active Withdrawn
- 2002-07-01 AU AU2002322481A patent/AU2002322481A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004538319A5 (enExample) | ||
| DK173585B1 (da) | Anvendelse af alfa-liponsyre til fremstilling af et lægemiddel til bekæmpelse af sygdomme fremkaldt af retrovirus | |
| RU2760682C2 (ru) | Стабилизаторы тучных клеток лечения гиперцитокинемии и вирусной инфекции | |
| KR101435242B1 (ko) | 간염치료용 실리비닌 성분 | |
| CA2710605C (en) | Anti - retroviral combination | |
| JP2005515966A5 (enExample) | ||
| JP2015512406A5 (enExample) | ||
| JP2010525050A5 (enExample) | ||
| JP2011516613A5 (enExample) | ||
| JP2007532663A5 (enExample) | ||
| US8017652B2 (en) | Activators of peroxisome proliferator-activated receptors | |
| JP2017514911A5 (enExample) | ||
| CN108367001A (zh) | 治疗丁型肝炎病毒感染 | |
| JP2009517411A5 (enExample) | ||
| WO2006092741A2 (en) | Treatment of inflammatory disorders with praziquantel | |
| JPS61286325A (ja) | 後天的免疫不全症の治療剤 | |
| JPH0232093A (ja) | 抗レトロウィルスジフルオロ化ヌクレオシド類 | |
| JP2008247822A (ja) | 鎮痛用組成物 | |
| JPH04346930A (ja) | 安定なアスピリン腸溶錠 | |
| JPH0352815A (ja) | 血管内血液凝固症候群の治療剤 | |
| JP2004522780A5 (enExample) | ||
| CA2703918A1 (en) | Solid pharmaceutical dosage forms of atazanavir and ritonavir combinations | |
| WO2020029441A1 (zh) | 尼克酰胺组合物在制备治疗索拉非尼手足皮肤反应药物中的应用 | |
| RU2120284C1 (ru) | Комбинированное противовоспалительное, анальгезирующее, жаропонижающее средство | |
| CN108135882A (zh) | 包含HMG-CoA还原酶抑制剂和ACE抑制剂的药物组合物 |